Generic Name and Formulations:
Serum-derived bovine immunoglobulin/protein isolate (SBI) 5g, dextrose 5g, sunflower lecithin (trace amounts); pwd; per packet; lactose-, gluten-, dye-, and soy-free.
Entera Health, Inc.
Indications for ENTERAGAM:
Clinical dietary management in patients with: limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or specific intestinal disorders (eg, irritable bowel syndrome with diarrhea [IBS-D], inflammatory bowel disease [IBD], and HIV-associated enteropathy).
Dissolve packet contents in at least 4oz (120mL) of water or other liquids; stir until fully mixed (do not shake); or, may be mixed in foods (eg, pudding, yogurt); consume dose immediately after mixing. Initially 1 packet twice daily for 2–4 weeks; may increase up to 4 packets daily. Maintenance: at least 1 packet daily.
<2yrs: see full labeling. ≥2yrs: Initially ½ packet daily; may increase dose based on response and tolerance.
Must use under physician supervision. Pregnancy, labor & delivery, nursing mothers: see full labeling.
Mild nausea, constipation, stomach cramps, headache, increased urination.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness